Impaired platelet [3H]paroxetine binding in female patients with borderline personality disorder

Psychopharmacology (Berl). 2005 Nov;182(3):447-51. doi: 10.1007/s00213-005-0097-1. Epub 2005 Oct 19.

Abstract

Rationale: There have been few studies of platelet paroxetine binding in borderline personality disorder (BPD).

Objective: Our aim was to determine whether female BPD subjects show abnormalities in platelet paroxetine binding.

Methods: Twenty-one female BPD subjects and 16 age- and gender-matched normal control subjects were assessed using the following: (1) Diagnostic Interview for Borderlines, Revised, (2) Diagnostic Assessment for Personality Pathology: Brief Questionnaire, and (3) Barratt Impulsivity Scale. Platelets were collected and assayed for platelet paroxetine binding.

Results: Bmax was lower in the BPD group (p < 0.0001), but differences in Kd only reached a trend level. There were no associations with trait dimensions independent of diagnosis.

Conclusions: Reduced platelet paroxetine binding in female BPD patients may reflect presynaptic serotonin dysfunction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Borderline Personality Disorder / metabolism*
  • Female
  • Humans
  • Palate / metabolism*
  • Paroxetine / metabolism*
  • Serotonin / physiology

Substances

  • Serotonin
  • Paroxetine